Gibson Christopher

Gibson Christopher, chief executive officer of Recursion Pharmaceuticals (RXRX) and Pacific Biosciences of California (PACB), has filed 61 Form 4 transactions across the two companies. The pattern is one-sided: zero open-market purchases and $8.06 million in open-market sales, all in RXRX. The seven most recent sales, spanning February through June 2026, were each in the $123,000 to $145,000 range, with the largest single transaction on June 5 at $144,800. The selling cadence is regular, roughly every two weeks. Sales occurred on June 5, May 22, May 7, April 22, April 7, March 23, and February 19. Each sale was paired with a code C conversion of derivative securities at zero dollar value, which is a mechanical step that makes shares available for sale. The company also withheld shares to cover taxes on February 6 ($36,895.84), February 17 ($95,154.85), and May 15 ($69,375.84), and made two gifts in March and May. The PACB activity is entirely different. Christopher received compensation grants (code A) on March 3, April 8, and June 3, all valued at zero. There are no PACB sales in the recent record. The contrast is clear: RXRX produces steady, modest open-market sales, while PACB produces only equity awards. The dollar amounts are small relative to a typical CEO stake, and the sales are spaced evenly, which suggests a scheduled disposition program rather than a reaction to price movement.